Sep 12, 2022 / 05:40PM GMT
Terence C. Flynn - Morgan Stanley, Research Division - Equity Analyst
Okay. Great. Thanks, everybody, for joining us. I'm Terence Flynn, the pharma -- pharma analyst here at Morgan Stanley. We're very pleased to be hosting Pfizer today. Before we get started, I've got to make a disclosure and then Pfizer is going to make one.
For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
Bryan Dunn - Pfizer Inc. - Senior Director, Investor Relations
Just before we get started here, we just want to remind you that we will be making forward-looking statements, which are subject to risks and uncertainties and the actual results may vary. Additional information regarding forward-looking statements is available under Risk Factors and forward-looking information and factors that may affect future results in our SEC
Pfizer Inc at Morgan Stanley Global Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot